SGLT1/2双靶点抑制剂的研究进展

Research progress in SGLT1/2 dual-target inhibitors

糖尿病是因胰腺产生不了足够的胰岛素或者人体无法有效地利用所产生的胰岛素时,而产生的慢性疾病。钠-葡萄糖协同转运蛋白(SGLTs)是跨细胞膜吸收葡萄糖的重要转运蛋白,其亚型SGLT1和SGLT2分别对胃肠道和肾脏吸收葡萄糖起着关键作用,SGLTs抑制剂是一类新型降糖药物。SGLT1/2双靶点抑制剂,通过对SGLT1与SGLT2的抑制,能减少肠道中的葡萄糖吸收,增加肾脏的尿葡萄糖排泄,从而有效控制血糖。近几年针对SGLT1/2双靶点抑制剂的研究日益增多,本文拟对其研究进展进行综述。

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces.Sodium-glucose cotransporters(SGLTs)are important transporters for the absorption of glucose across the cell membranes.Subtypes SGLT1 and SGLT2 play a key role in the absorption of glucose in the kidney and gastrointestinal tract.SGLTs inhibitors are a new type of hypoglycemic drugs.SGLT1/2 dual-target inhibitors can effectively control the blood glucose by inhibiting the SGLT1 and SGLT2 targets,reducing glucose absorption in the intestine and increasing urinary glucose excretion in the kidney.In recent years,the research on SGLT1/2 dual-target inhibitors has been increasing rapidly.This article mainly reviewed the research progress in SGLT1/2 dual-target inhibitors.